Phenox

Phenox is a provider of medical technology for the development of devices for the treatment of neurovascular diseases. The company's technologies offer a wide range of treatment options, including basic intervention technologies, as well as mechanical thrombectomy devices for the treatment of complex intracranial aneurysms and dissections, allowing endascular specialists to obtain the necessary technologies for the treatment of ischemic and hemorrhagic stroke.

History

2022: Wallaby Medical bought Phenox for €0.5 billion

On April 21, 2022, Wallaby Medical, a company specializing in the development and commercialization of neurovascular interventional products for the treatment of stroke, announced the acquisition of the German Phenox GmbH, including the Phenox-owned company Femtos GmbH.

The deal worth €500 million, which received all the necessary regulatory approvals, has already been closed, all phased payments have been made. Wallaby funded the acquisition of Phenox from funds received during the Series D funding round with the support of leading health investors.

Wallaby Medical bought Phenox for €0.5 billion

Wallaby and Phenox have been strategic partners since 2019. Phenox is the exclusive distributor of the Avenir coil system as well as the Esperance aspiration catheters of Wallaby in the United States and in the European market.

According to Wallaby Medical, the acquisition will allow the combined company to become a world leader in providing a wide range of neurovascular technologies and solutions around the world, including in the USA, China, Europe, Japan and other international markets.

Michael Alper, CEO of Wallaby, will become head of the combined company. Professor Hermann Monstadt, MD, founder of Phenox, will take over as managing director of Phenox. All existing brands of Phenox products will be retained, the company said.^[1]

Notes